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ABSTRACT  
Challenges in the assessment, diagnosis and management of severe, difficult-to-control asthma are increasingly regarded as 
clinical needs yet unmet. The assessments required to determine asthma severity, comorbidities and confounding factors, 
disease phenotypes and optimal treatment are among the controversial issues in the field.  
The respiratory care experts’ input forum (RC-EIF), comprised of an Iranian panel of experts, reviewed the definition, 
appraised the available guidelines and provided a consensus for evaluation and treatment of severe asthma in adults.  
A systematic literature review followed by discussions during and after the forum, yielded the present consensus. The expert 
panel used the appraisal of guidelines for research and evaluation-II (AGREE-II) protocol to define an initial locally-adapted 
strategy for the management of severe asthma.  
Severe asthma is considered a heterogeneous condition with various phenotypes. Issues such as assessment of difficult-to-
control asthma, phenotyping, the use of blood and sputum eosinophil count, exhaled nitric oxide to guide therapy, the 
position of anti-IgE antibody, methotrexate, macrolide antibiotics, antifungal agents and bronchial thermoplasty as well as 
the use of established, recently-developed and evolving treatment approaches were discussed and unanimously agreed upon 
in the panel.  
A systematic approach is required to ensure proper diagnosis, evaluate compliance, and to identify comorbidities and 
triggering factors in severe asthma. Phenotyping helps select optimized treatment. The treatment approach laid down by the 
Global Initiative for Asthma (GINA) needs to be followed, while the benefit of using biological therapies should be weighed 
against the cost and safety concerns.
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THE RESPIRATORY CARE EXPERTS’ INPUT 
FORUM AND SEVERE ASTHMA  
When a patient requires high intensity inhaled 
corticosteroids (HICS) and a  long-acting beta-agonist 
(LABA) and/or systemic corticosteroids (CS) to prevent 
his/her asthma from becoming uncontrollable,  or if the 
symptoms remain uncontrollable despite adequate 
therapy, the condition is referred to as severe, difficult-to-
control asthma (1). According to the GINA, asthma 
severity is assessed retrospectively from the level of 
treatment required to control symptoms and exacerbations.  
Severe asthma requires step 4/5 (moderate- or high-dose 
ICS/LABA ± add-on); it may remain uncontrolled despite 
treatment (GINA 2014). 
Despite notable advances in the diagnosis and 
treatment of asthma, its severe and refractory form still 
poses a clinical challenge (2). The recent international 
guidelines including the GINA (3) and ERS/ATS 
(European Respiratory Society and American Thoracic 
Society) (4) have laid down clinical recommendations for 
diagnostic and therapeutic approaches to severe asthma. 
However, these recommendations need to be customized 
for local implementation. Using the AGREE-II protocol (5), 
the Iranian panel of scientific experts in the field of 
pulmonary medicine came together in a Respiratory Care 
Experts’ Input Forum (RC-EIF) to formulate a statement on 
the diagnosis and management of  severe, difficult-to-
control asthma.  
This report is an overview of debates within the RC-EIF 
held in December 2014, in Iran. The present article 
provides a literature review on clinical issues in the 
diagnosis and management of severe asthma and a 
consensus on implementation of international guidelines in 
a local setting.  
The aim of this RC-EIF report is to define clinical 
parameters of severe asthma, the phenotypes and   
recommendations for management of severe asthma based 
on available evidence, current international guidelines and 
input  of experts involved in severe asthma management in 
adults. This report may also provide the basis for the 
development and implementation of locally-adapted 
guidelines on severe asthma management in the future. 
 
INTRODUCTION 
Around 6.5% of the Iranian population have asthma; 
the prevalence is increasing in major cities (6-11). Given the 
health burden of the disease, the national asthma and 
allergy strategy based on GINA and other international 
widely-referenced guidelines needs to be developed and 
implemented. The importance and necessity of having 
comprehensive national guideline for asthma should be 
further emphasized with certain criteria for referral.  
Beside the recently drafted and approved national 
guideline for asthma care addressing level-one and -two 
healthcare providers (general practitioners, family 
physicians and internists), a solid locally-adapted 
approach to subcategories of asthmatics and severe asthma 
patients needs to be defined.  
Despite the fact that many asthmatic patients may be 
effectively controlled using the available medications, there 
is a subset of patients who remain refractory (12). These 
patients have considerable health expenditures (13, 14). 
There is much to be answered regarding the possible 
underlying mechanisms governing asthma unresponsive 
to treatment and the best approach to manage such 
patients. The definitions of severe/refractory asthma were 
agreed upon as variations of such patients had been 
adopted previously (15). Just recently, an American-
European task force comprised of clinicians and scientists 
with special expertise in severe asthma was established to 
revisit previous definitions, define possible phenotypes of 
severe asthma, propose methods for its evaluation and 
provide recommendations on treatment (4).  Severe asthma 
is regarded as a heterogeneous disease, with various 
phenotypes.  The investigations suggested phenotypic 
biomarkers and targeted biologic therapies which partly 
succeeded to show efficacy (4). 
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MATERIALS AND METHODS 
A. The expert panel composition and consensus  
A panel of experts from pulmonary medicine and allied 
fields discussed the current evidence, limitations and 
clinical peculiarities in the management of severe and 
refractory asthma. Each participant was selected based on 
clinical expertise and academic records in the field of 
asthma. All experts interacted in contextual question-based 
round table discussions during this forum.  A systematic 
approach toward key issues was taken including:               
1) definition and clinical correlates of severe asthma,          
2) assessment of comorbidities and contributory factors,   
3) approaches to asthma phenotyping, and 4) treatment 
options. The available information together with  expert 
opinions were compiled to draw a consensus. 
Following a systematic literature search, documents 
featuring clinical perspectives of severe asthma and 
recommendations for the diagnosis and treatment were 
isolated for review and discussions. The most recent 
guidelines (3, 4) and related scientific publications were 
circulated among all RC-EIF attendees two months prior to 
the event.  
After defining a list of contextual questions, a series of 
plenary talks and interactive round table discussion were 
conducted; the AGREE-II protocol was employed to 
appraise international guideline statements for local 
implementation. The AGREE-II protocol which can be 
applied to any set of guidelines in health care such as 
health promotion, public health, screening, diagnosis, 
treatment or interventions is perhaps regarded as one of 
the simplest methods of appraising and customizing 
international guidelines for locally-adapted strategies (5).  
The section moderators of this EIF proposed several 
questions related to the definition and characteristics, 
diagnosis and treatment of severe asthma. These 
contextual questions (CQs) were defined two weeks prior 
to the meeting with key CQs on the diagnosis and 
treatment of severe asthma isolated and ranked by priority. 
Five CQs were selected to be explicitly discussed to 
provide clinical insight into optimal, evidence-based care 
in severe asthma.  
The panel assessed the evidence in response to each CQ 
and appraised international guidelines on using the 
AGREE-II protocol. The expert panel further evaluated the 
outcomes of interest for each question in ameliorating the 
burden of severe asthma. The CQs assessed the research 
evidence and available international guidelines  outlined 
below (Figure 1).  
CQ1: With regard to asthma care, how can healthcare 
providers’ adherence to guidelines affect healthcare 
outcomes? 
CQ2: Based on the latest international guidelines (GINA, 
ERS/ATS), what are the knowledge and practice gaps for 
management  of severe asthma in our setting? 
CQ3: How are severe/refractory asthma comorbidities and 
contributory factors  characterized and evaluated?  
CQ4: Where should we place  ICS, ICS/LABA and LTRAs 
and the newer therapies including monoclonal antibodies 
in the hierarchy of management of adults with 
severe/uncontrolled asthma? 
CQ5: With regard to asthma care, how may adherence to 
guidelines by healthcare providers affect clinical 
outcomes?  
 
 
 
 
 
 
 
 
 
 Figure 1. When addressing the five contextual questions (CQs) associated with 
the clinical decision   in severe refractory asthma management, the outcomes of 
Interest for each question in ameliorating the burden of severe asthma were also     
discussed based on   research evidence and available international guidelines on 
severe asthma.  ICS: Inhaled corticosteroids, LABA: Long-acting beta-agonists, 
LTRAs: Leukotriene receptor antagonists.   
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B. Literature review  
A systematic literature search in PubMed, MEDLINE, 
Scopus, Cochrane Central Register of Controlled Trials and 
Google Scholar databases (1990-2014) was done using a 
combination of keywords including severe asthma, 
refractory asthma, phenotyping, severe asthma 
management and recommendations. Following 
evaluations, documents featuring clinical perspectives of 
severe asthma and recommendations for the diagnosis and 
treatment approaches were isolated for review and 
discussion. When there were no randomized controlled 
trials (RCT) available with respect to the outcome of 
interest, the best available evidence to support or abrogate 
the clinical approach was considered. After the EIF, a 
systematic review was done to ensure all RCTs and related 
research was retrieved and assessed. The summary of 
evidence was reviewed and commented upon by the 
expert panel both during and after the meeting through 
face-to-face discussions and conference calls, respectively. 
The reviewed original documents were examined to   
judge available evidence. 
The definition of severe asthma was discussed and 
agreed upon on  the basis of previous (16) and more recent 
(17, 18) studies according to ATS/ERS’ task force definition 
for asthma control and severity (4). With regard to asthma 
phenotyping, severe asthma evaluation and treatment 
approach, the relevant literature was reviewed and 
combined  with the experts’ views to arrive at a practical   
agreement or consensus.  
RESULTS AND DISCUSSIONS 
The literature review and experts’ views obtained 
during our RC-EIF summarized the following: 1) 
Assessments needed to determine severe, difficult-to-
control asthma, 2) Evaluation of comorbidities and 
confounding factors, 3) Early phenotyping as an essential 
step in optimized therapy, and 4) Current treatment 
approaches. The recommendations were made with data at 
hand and the basis of the AGREE-II protocol appraising 
international guidelines (GINA, ERS/ATS) in line with 
adopted strategies.  
C. The assessments needed to determine severe, difficult-to-control asthma i. Evidence review 
Generally, patients with over six months of 
symptomatic air flow limitation , restriction of function, or 
chronic, incapacitating asthma and severe, acute 
exacerbations (in spite of continued medication) are 
considered to have severe asthma (12). However, 
according to the literature, up to 30% of non-asthmatic 
patients may falsely be diagnosed as severe, difficult-to-
control asthma (19, 20). The initial assessments should 
entail careful history-taking regarding symptoms such as 
cough, wheezing, dyspnea (upon exercise), and nighttime 
awakenings. Additional information about the 
environmental or occupational factors and factors 
contributing to exacerbation should be obtained. Often, the 
obesity-related disordered-breathing is mistaken with 
asthma (21, 22).  
In fact, individuals should be assessed for other 
conditions, which may mimic asthma or be associated with 
it. Assessment of reversible airflow limitation (including 
inspiratory and expiratory loop-spirometry, before and 
after bronchodilator use) should be performed as part of 
asthma diagnosis (23, 24). Medications may need to be 
withheld to better assess the reversibility of symptoms. In 
case of inconsistencies among history, physical findings 
and spirometry results, and when lung function is 
relatively preserved, confirmatory pulmonary function 
evaluations such as diffusing capacity, as well as 
bronchoprovocation with methacholine or exercise 
challenge test may be warranted (25, 26).  
The routine use of chest high-resolution computed 
tomography (HRCT) scans in patients with suspected 
severe asthma based on history, presenting symptoms 
and/or results of other evaluations, is open to debate. 
Based on the experts’ views in the present EIF, the use of 
chest HRCT should depend on the results of earlier tests 
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performed in the diagnostic pathway. For instance, in 
patients with suspected allergic bronchopulmonary 
aspergillosis, with a positive prick test to aspergillus 
antigen, chest HRCT would be clinically indicated (19, 27). 
Meanwhile, the question of whether chest HRCT is needed 
in patients with severe asthma or not (without other solid 
indications for that test) was discussed based on the 
evidence. 
Having searched the literature, we could not locate any 
systematic review or longitudinal reports investigating the 
results of chest HRCT use to screen for masquerading or 
comorbid conditions in patients with severe asthma. We 
however retrieved some related observational studies the 
majority of which did not report on masquerading or 
comorbid conditions (27-30). Two of these observational 
reports were case series and revealed no data about the 
number of sampled patients (31). In one report, the 
comorbid/masquerading condition was diagnosed before 
HRCT was done (32) and in some other studies, HRCT was 
selectively done upon apparent indications other than the 
presumed severe/uncontrolled asthma (33-37).  
Taken together, five reports provided inconsistent 
results of chest HRCT in severe asthma patients (38-42). In 
a report by Grenier et al, 30% of asthma cases who 
demonstrated no obvious change in serial chest 
radiography were found to have bronchiectasis on HRCT. 
However, only less than 15% of these patients fulfilled the 
criteria of severe asthma (38). Paganin et al. reported 13 
and 37 patients with possible severe asthma and no specific 
selection criteria in two studies where the sampled 
population was undescribed (39, 40). In both reports, most 
patients were found to have either bronchiectasis or 
emphysema on HRCT. In a retrospective analysis by 
Jensen et al, 20% of severe asthma patients who had HRCT 
for unreported reasons demonstrated bronchiectasis (37). 
When the HRCT of severe asthma patients was compared 
with cases with bronchiolitis obliterans, the only more 
pronounced finding in patients with severe asthma was the 
mosaic pattern of attenuation. Bronchial dilatation was 
reported in 50% of severe asthmatic patients (43). In a 
recent report by Boulet et al, the HRCT in corticosteroid-
naive mild stable asthmatic patients revealed no 
bronchiectasis while some patients showed emphysema-
like changes (of which the majority were smokers) (43). A 
report by Takemura et al. demonstrated bronchial 
dilatation in few patients who had severe asthma 
according to GINA (41). Lastly, in a case series of 68 elderly 
subjects in whom asthma was unlikely to be severe (with 
an FEV1  of 77% and 100% among early-onset and late- 
onset cases) (42) HRCT revealed emphysema and bronchial 
dilatation in 21% and 13% of early-onset asthma cases, 
respectively.   
Our systematic literature search returned no studies 
indicating the prevalence of other masquerading or 
comorbid findings in severe asthma patients. Our search 
did not provide any report on the accuracy of chest HRCT 
in severe asthma. With reference to the international 
guidelines, neither GINA (3) nor other current guidelines 
(4) had made any recommendations regarding the position 
of chest HRCT in severe asthma.  
 ii.  Experts’ statement 
1. Based on the reviewed evidence, our expert panel 
suggested that the use of chest HRCT should only be 
considered upon atypical presentation in patients 
suspected for severe asthma. Atypical presentations 
include excessive mucus production, lung function 
deterioration and diminished carbon monoxide transfer 
factor coefficient. 
2. Careful history-taking and physical examination, 
spirometry of both inspiratory and expiratory loops 
pre- and post-bronchodilator usage and when 
indicated, complete pulmonary function tests including 
diffusing capacity should be considered as assessment 
measures in severe, difficult-to-control asthma. 
However, severe airflow limitation (FEV1<50% 
predicted or <1.0L) is a contraindication to 
bronchoprovocation with methacholine test (25). 
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D.  Evaluating comorbidities and confounding factors i. Evidence review 
The common causes of admission of asthmatic patients 
to the intensive care units include the continued exposure 
to triggers or second-hand smoke (44, 45), incomplete 
assessment of comorbidities like sleep disordered 
breathing (SDB) including obstructive sleep apnea 
syndrome (OSAS) (46, 47),  gastroesophageal reflux disease 
(GERD) (48, 49), or Aspirin-Exacerbated Respiratory 
Disease (AERD) (50) lack of adherence to medication (51, 
52), inadequate follow-up (53) and varied response to 
medications (54). Severe, uncontrolled asthma is frequently 
associated with comorbidities and the lack of adherence to 
treatment should always be considered in such cases. 
Based on the evidence, lack of adherence may be seen in as 
many as 55% of severe asthma patients (19, 55, 56). Poor 
knowledge on proper use of inhalers is common among 
patients and needs to be carefully addressed (57). Methods 
measuring the compliance to ICS use are not widely 
applied in clinical practice. While pressure-actuated 
counters are only available on some new devices, canister 
weight is almost always a useful measure.  On the other 
hand, the adherence to oral medications can be assessed 
through examining serum prednisolone, theophylline, 
systemic CS side effects and suppression of serum cortisol 
levels. Strict policies should be defined to ensure that 
patients get the prescriptions refilled only after their 
physicians’ order (56). In the event of non-adherence, 
clinicians may plan to develop interventions to improve 
patients’ level of adherence to therapy (53). The treatment 
cost per se may have a substantial effect on this (58).  
While allergy and atopy have a solid association with 
asthma, large epidemiologic studies have shown that 
severe asthma is less linked with allergy as compared to 
mild to moderate asthma (59). Nevertheless, even in severe 
asthma, detection of any association between a specific IgE 
(revealed by skin prick or serum testing) through an 
ongoing exposure and the symptoms may help in 
identifying a contributory factor to asthma exacerbations 
(60). 
Rhinosinusitis has been reported in a vast majority of 
asthmatic patients (61, 62). Meanwhile evidence for nasal 
polyps has been found in a fraction of asthmatics especially 
those with cystic fibrosis or primary ciliary dyskinesia (61, 
63). The prevalence of NSAID sensitivity or AERD is <5%, 
however it may affect 20 to 40% of patients with asthma 
associated with chronic rhinosinusitis and nasal polyps 
(64). 
While GERD is reported in almost 70% of asthma 
patients (48, 65, 66), anti-reflux treatments have resulted in 
moderate or no benefit in the control of asthma symptoms 
(67, 68). The term ‘silent GERD’ as an underlying 
contributor to poor asthma control may  have been 
overestimated; however assessment for occult GERD and 
related treatments in case of confirmed diagnosis should 
always be considered (68). The symptoms arising from 
GERD and rhinosinusitis may not only hamper vocal cord 
function but also masquerade as asthma (69). 
Obesity is another comorbidity linked with severe and 
difficult-to-control asthma. Its  association with asthma 
may largely depend on the age at onset (70, 71). 
Sadly, the worldwide health threat, smoking, has 
become more popular among youngsters in our 
community over the past decades (72-77).   It can make 
asthma more difficult-to-control (78). The inflammatory 
processes seem to be altered in smokers leading to an 
attenuated response to CS (79, 80). Some reports have 
suggested testing the urinary and salivary cotinine in 
asthmatic patients as the test often reveals evidence of 
exposure to second-hand smoke (81-83). On the other 
hand, environmental factors such as ozone levels are 
directly linked with asthma outcomes in urban populations 
(84, 85). Given the critical importance  of air pollution in 
our major cities, well-designed studies on environmental 
exposures and severe asthma are urgently required. 
The prevalence of anxiety and depression in adults 
with severe asthma has reached 50% in some reports (47, 
86-88). Such conditions are frequently subject to oversight. 
Therefore, when indicated, a proper psychiatric assessment 
and providing the required care is imperative (89). There 
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are no established psychological interventions to help 
behavioral aspects of asthma. A Cochrane meta-analysis 
has evaluated various relaxation and behavioral 
interventions in asthma patients showing moderate  
benefits in asthma outcome (90).  
Lastly, when addressing asthma-related comorbidities, 
therapy-induced issues pertaining to the overuse of 
inhaled and systemic CS should also be considered (91-93). 
 ii. Experts’ statement 
1. Asthma is frequently linked with various comorbidities 
such as rhinosinusitis, GERD, OSAS, AERD, and 
psychopathologies. The environmental factors and lack 
of adherence to therapy may often give rise to difficult-
to-control asthma.  For many of these, how the 
conditions interact with asthma is yet to be further 
explained especially in case of severe asthma 
2. . When relevant, comorbidities should be appropriately 
treated as they may affect the outcome.  
 
E.  Early phenotyping an essential step in optimized therapy  i. Evidence review 
Severe asthma is unanimously recognized as a 
heterogeneous condition meaning that not all patients 
respond similarly to a given therapy or demonstrate a 
comparable clinical course. Asthma phenotyping does not 
follow a standard paradigm; hence no commonly-accepted 
definition of specific asthma phenotypes are available yet. 
Nonetheless, defining the specific characteristics of asthma 
phenotypes may not only help promote targeted therapies 
but also help define the expected course of the disease in 
some patients (94, 95). As such, studies have proposed 
some characteristics including eosinophilic inflammation, 
T helper-2 (Th2) processes and obesity as phenotype 
determinants. Such determinants can be helpful upon 
prescribing non-targeted (CS) or targeted (LTRA, anti-IgE, 
anti-IL5 and anti-IL13 antibody) therapies in asthmatics 
(71, 95-101).  
  The presence of neutrophilic inflammation in the 
sputum of patients with difficult-to-control asthma has 
been associated with diminished response to CS therapy 
(99). Although such measurements are available at referral 
centers in our country, their utility and methodology need 
to be standardized before suggesting wide usage. 
Some studies with clinical inconsistencies both in the 
definition of asthma exacerbations and the cut-off level of 
eosinophils in the sputum enrolled a relatively low number 
of subjects and the examinations appeared to be 
insufficient (99, 102, 103). One study concluded a possible 
decrease in treatment costs of severe asthma in a single 
hospital setting once the treatment was guided via sputum 
eosinophils count (99). When attempting to characterize 
severe asthma and individualized care, a contextual issue 
is whether severe asthma treatment should be guided by 
sputum eosinophil count, rather than clinical criteria alone. 
Since the clinical advantage of sputum eosinophil-guided 
treatment vs. treatment guided by clinical criteria alone is 
uncertain, further evidence is required to suggest 
phenotyping in asthma patients based on sputum 
eosinophil count.  
 Other potential biomarkers for Th2 inflammation 
include exhaled nitric oxide (FeNO) and blood eosinophils 
(98, 104, 105). FeNO may not be elevated in younger 
patients with chronic asthma, and a low level is suggestive 
of conditions such as cystic fibrosis and ciliary dyskinesia 
(105, 106). 
Except for blood eosinophils, other biomarker 
measurements in asthma need specialized equipment and 
assays, which are not readily available. Moreover, the 
utility of these biomarkers to identify clinically- and 
therapeutically-distinct phenotypes should be further 
examined (107, 108).  
Bronchial thermoplasty (BT) is a recently validated 
method shown to improve control in severe persistent 
asthma. Some recent evidence supports the fact that BT 
reduces asthma-associated systemic markers of allergic 
inflammation including blood eosinophils (109). Patients 
with severe persistent asthma and particularly those of 
eosinophilic phenotype, who demonstrate continued 
symptoms despite the adequate use of inhaled 
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corticosteroids and long-acting !2-agonists, may benefit 
from BT (109, 110). 
 ii. Experts’ statement 
1. Severe asthma is regarded as a heterogeneous 
condition characterized by the need for aggressive 
treatment with high intensity inhaled corticosteroids in 
combination with LABA + add-on.  The condition 
comprises various pathophysiological phenotypes for 
which the net definitions are not agreed upon. Such 
heterogeneity hinders the characterization of the 
disease and selection of appropriate treatment. Our 
improved understanding about the various phenotypes 
of severe/ difficult-to-control asthma and the 
biomarkers for each of these phenotypes may assist us 
in optimizing treatment for severe asthmatics . 
2. The cost vs. utility of biomarker  (blood/sputum 
eosinophilia and/or FeNO)-guided treatments should 
be better examined before recommending  wide usage 
of these tests in   routine  asthma management.   
 
F. The established, recently-developed and evolving treatment approaches for severe asthma 
While the efficacy of traditional controller medications, 
such as long-acting beta-agonists, leukotriene receptor 
antagonists and theophylline is well-supported in the 
management of asthma (111-113), their clinical use has not 
been well-documented in severe, difficult-to-control 
asthma. In many instances, a mixed combination of these 
medications may be required (113). LABAs are 
recommended for use in combination with ICS only (114).  
When salmeterol and formoterol are used without steroids, 
they are shown to increase the risks of more severe attacks 
(114). 
 i. Evidence Review 1. Using established asthma medications a. Corticosteroid insensitivity 
As discussed earlier in this report, severe asthma 
involves CS insensitivity; hence, despite adequate CS 
therapy asthma control may remain poor. Therefore, 
although CS is the mainstay of treatment in mild to 
moderate asthma, alternative molecular-targeted therapies 
may be sought to ameliorate inflammation and enhance CS 
sensitivity in severe asthma (115). Patients with severe, 
difficult-to-treat asthma tend to become dependent, 
refractory or insensitive to corticosteroids (116).  To 
maintain even a partial control of severe asthma 
symptoms, up to one-third of such patients would require 
oral CS in addition to ICS (66). Based on two reports, the 
intramuscular injection of high-dose triamcinolone, partly 
recovered asthma symptoms, diminished sputum 
eosinophils and improved FEV1 (117, 118). These findings 
support a relative insensitivity to such a treatment rather 
than a full resistance.   
Corticosteroid insensitivity is likely associated with 
various comorbidities including smoking (119), obesity 
(120), vitamin D deficiency (121, 122), and non-eosinophilic 
inflammation in adults (123).  
While the eosinophilic phenotype with high IL-5 and 
IL-13 levels, tend to respond to ICS in mild to moderate 
asthma, eosinophilic inflammation remains persistent in 
some asthmatics despite adequate ICS or  even systemic CS 
therapy (59, 124, 125). The non-eosinophilic phenotype 
comprises a larger subgroup of asthma patients (125). A 
clear understanding of possible mechanisms underlying 
CS insensitivity has led to the development of novel 
treatments including p38 mitogen-activated protein kinase 
(MAPK) inhibitors (126) and histone deacetylase-2 (HDAC-
2) recruiters (127). 
Some immunomodulatory and immunosuppressive 
agents including cyclosporine A, gold salts, intravenous 
immunoglobulin G and methotrexate have been widely 
studied for their steroid-sparing properties in severe 
asthma. Despite the evidence showing improved CS 
sensitivity with these agents, their clinical benefits do not 
outweigh potential side effects (128-131). 
 b. Inhaled and oral CS therapy 
The threshold daily doses of ICSs are outlined in Table 
1. These are higher than the usual doses required to 
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achieve maximal therapeutic effects in milder asthma. 
There is individual variation in dose-efficacy of ICS with 
evidence suggesting that greater ICS doses may show 
greater efficacy in severe asthma (132, 133). Together, there 
seem to be insufficient data to support higher doses (over 
2000 mcg/day) of ICS and ultra-fine particle ICS in severe 
asthmatics.  
To control severe asthma, physicians may need to even 
quadruple the dose of ICS in some cases (134). 
Quadrupling the dose is not often practical in severe 
asthma since the patients are already maintained on high 
ICS doses (134, 135). As a result, once standard therapies 
are found insufficient, OCS is added to help induce and 
maintain control in severe asthma. Meanwhile, it has 
remained unclear whether low-dose continuous OCS 
should be preferred over multiple bursts to control 
exacerbations. 
In case of continuous use, clinicians should be well-
versed about the potential untoward effects of systemic 
and inhaled corticosteroids including the increased risk of 
fractures, cataracts, an increased risk of adrenal 
suppression and growth retardation in children, 
respectively (136-139). The weight gain induced by chronic 
use of systemic CS may per se have a negative impact on 
asthma control (140, 141). As per the recent guidelines, 
when systemic CS are continuously used, prophylactic 
measures should be taken to prevent loss of bone density 
(142). 
 Table 1. The threshold daily dose of inhaled corticosteroids in picograms 
considered as high in adults. The presumed high doses are provided from the 
summary of product characteristics.  
 Inhaled corticosteroid Threshold daily dose in pg. considered as high in adults 
Beclomethasone 
dipropionate 
>1000 (DPI) >500 (HFA MDI) 
Budesonide >800 (MDI or DPI) 
Ciclesonide >320 (HFA MDI) 
Fluticasone propionate >500 (HFA MDI or DPI) 
Mometasone furoate >400 (DPI) 
Triamcinolone acetonide >2000 
DPI: Dry powder inhaler; HFA: Hydrofluoroalkanes; MDI: Metered-dose inhaler. Pg: picogram 
c. Short- and long-acting beta-adrenergic bronchodilators 
Patients with severe asthma frequently suffer from 
persistent airflow limitation despite adequate treatments 
(1, 4). In some patients with severe asthma, the incremental 
dose of ICS, together with a long-acting beta-agonist 
(LABA) provides a more favorable control than the use of 
ICS alone. As such, patients with refractory asthma may 
demonstrate at least a partial response and reach a more 
tolerable state, even though their composite asthma control 
indices (such as Asthma Control Questionnaire-7 or 
Asthma Control Test, ACQ-7/ACT, respectively) fall 
within uncontrolled levels (132, 143, 144).  
In some patients known to have ‘brittle’ asthma (those 
of rapid onset asthma with vigorous exacerbations), 
subcutaneous administration of the beta-agonist, 
terbutaline, has been tried but no comparative advantage 
of this approach over the repeated inhaled beta-agonist has 
been documented (145). 
It should be noted that continuous and high dose of 
beta-agonists can paradoxically result in lack of asthma 
control in mild to moderate patients. This becomes more 
evident when patients are continuously treated with high 
doses of short-acting beta-agonists (SABAs) or LABAs 
without ICS (146-148). Severe asthmatics are frequently 
prescribed with LABAs plus ‘as-needed’ SABAs. There has 
been an association between increased rate of mortality 
and the use of beta-agonists especially when these agents 
are used beyond the recommended limits (92, 146, 148). 
In   severe asthma, the dose and treatment duration of 
beta-agonist agents frequently exceed those recommended 
by guidelines and this makes it hard to comment on the 
presumably safe upper dose limit.  Some case reports have 
indicated that a medically-supervised decrement in the 
dose of beta- agonists in some severe adult asthma patients 
who take excessive beta-agonists has led to an improved 
asthma control (149).  
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To prevent the overuse of beta-agonists in severe 
asthma patients, especially in those showing side effects 
including tremor and palpitations and to help control 
asthma exacerbations, the use of ipratropium bromide 
aerosols is a supported option (150, 151). Although less 
effective, it is considered safer than beta-agonists and can 
be used as-needed during the day. The routine use of 
nebulizers has not been supported owing to a relative 
inefficiency in drug delivery. On the other hand, the use of 
pressurized metered dose inhalers (pMDI) with a spacer is 
recommended in severe asthma and upon exacerbations 
(152). 
 d. Slow-release theophylline 
In moderate asthma, symptom control can be achieved 
when theophylline is added to ICS (113). Theophylline 
(plus low dose ICS) has also been shown to enhance peak 
expiratory flow rates and lead to asthma control in 
smoking asthmatics, who demonstrated CS insensitivity 
(153). It is then plausible that theophylline improves CS 
insensitivity in some cases. Nevertheless, no such 
investigation has been done in adults with severe asthma.  
 e. Modifiers of the leukotriene pathway 
The well-established anti-inflammatory activity of 
corticosteroids, does not extend to inflammation mediated 
through the leukotriene pathway in the airways of 
asthmatic patients (154). Leukotriene receptor antagonist 
(LTRAs) can further reduce inflammation and improve 
symptoms when added to ICS therapy. The addition of a 
LTRA to ICS has led to improved lung function in three 
studies, which recruited adults with moderate to severe 
asthma not taking LABAs. Two of these reports were from 
aspirin-sensitive asthmatics in which 35% were on 
systemic CSs (155-157). However, in a study on 72 adults 
with severe asthma who were receiving LABA and ICS, 
adding montelukast failed to improve clinical outcomes in 
a two-week follow up (158). 
 On the other hand, in CASIOPEA study, montelukast 
added to the usual dose of budesonide in patients with 
mild to moderate asthma, significantly improved asthma 
control, regardless of patients’ ICS dose. The onset of 
action was faster (evident from day-1) in ICS + 
montelukast vs. ICS + placebo treatment arm (159).  In 
IMPACT study, the combination of fluticasone and 
montelukast showed equal efficacy to the combination of 
fluticasone and salmeterol. Patients receiving salmeterol 
plus fluticasone had a significantly higher incidence of 
drug-related adverse events compared to patients 
receiving montelukast plus fluticasone (10.0% vs 6.3%; 
P=0.01). Patients receiving salmeterol plus fluticasone had 
a significantly higher incidence of serious adverse 
experiences (7.4% vs 4.6%; P=0.022) (160). Furthermore, 
add-on montelukast in patients with mild to moderate 
asthma, insufficiently-controlled with ICS or ICS+LABA in 
a six-month prospective open-label observational study 
(MONICA), improved both asthma control and asthma-
related quality of life (161). Based on the subanalysis of 
MONICA study, add-on montelukast significantly 
improved asthma symptoms over 12 months in all patients 
in the study. Asthma control improved in all patient 
subgroups. In addition, comorbid allergic rhinitis, younger 
age, shorter duration of asthma and treatment with only 
ICS and not ICS+LABA, were found to be indicators of 
better control with add-on montelukast (162) 
Compared to LABAs, montelukast is less effective 
when added to ICS therapy in preventing exacerbations in 
moderate-to-severe asthma (163). Meanwhile, our 
systematic search yielded some more recent reports 
indicating the positive role of montelukast in treating both 
severe and mild forms of asthma (164-166). Using lung 
function tests and HRCT imaging, one study showed that 
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add-on therapy with montelukast improves distal lung 
function reflected by air trapping (but not airway wall 
thickness) in moderate-to-severe asthma (165). Based on 
the recent practice guideline, LTRAs are suggested as 
phenotype-guided treatment in patients with AERD 
(GINA 2014). Further research is needed to address the role 
of montelukast in severe asthma and to see whether 
aspirin-sensitive asthma phenotype responds better to 
montelukast than other phenotypes. 
 f. Long-acting muscarinic antagonists 
When moderate- to high-dose ICSs with or without 
LABAs fail to help severe asthma symptoms, the use of 
tiotropium bromide may improve lung function and lead 
to symptom control (167, 168). In patients receiving high-
dose ICSs and LABAs, adding tiotropium bromide 
provided improvement in FEV1 and diminished the as-
needed use of short-acting beta2-adrenergics. The 
combination can also slightly decrease the risk of severe 
exacerbations (167, 169). 
 2. Specific approaches directed towards severe asthma 
Until recently, research endeavors to investigate the 
optimized treatments for severe asthma were trivial.  This 
landscape is however rapidly changing now. Several well-
designed trials are ongoing to investigate the novel 
molecular-targeted therapies in the adult population 
suffering from severe asthma The evidence on safety 
profile of these new treatment options is however scant 
and continues to evolve (97, 98, 104, 170-176).  
For the time being, omalizumab is the only biologic 
drug available in clinical practice (177-181). To overcome 
the shortcomings of this drug, more recent investigations 
have introduced new monoclonal antibodies possessing a 
higher avidity towards IgE (e.g. ligelizumab and 
lumiximab) (182, 183). Many biological drugs with various 
mechanisms of action are being developed and 
investigated today. As already mentioned, it is crucial to 
identify asthma phenotypes as it would significantly help 
in selecting the most appropriate drug for the individual 
patient (182). Based on the phenotypes, the eosinophilic 
asthma cases are expected to better respond to Th2 
pathway modifiers. As such, the promising agents, which 
target cytokines of Th2 pattern including IL-2, IL-13 or IL-5 
(daclizumab, mepolizumab and lebrikizumab, 
respectively), are expected to offer favorable control in 
asthmatic patients with hypereosinophilia (115, 182).  A 
review of randomized data on new treatments in severe 
asthma has been outlined in Table 2.  
 ii. Experts’ statement 
The combination of ICS and one or two additional 
controllers including LABA, LTRAs or oral theophylline 
remains the mainstay pharmacotherapy for severe, 
difficult-to-control asthma.  Tiotropium bromide is an 
effective add-on controller therapy to ICS in severe asthma. 
No empirical data has suggested the advantage of multiple 
combinations of the above alternative controllers in the 
management of severe asthma. Therefore, one should 
monitor clinical parameters to ensure the optimum 
combination of the controller medications. In case of 
properly obtained and maintained control, upon clinical 
discretion, the treatment regime can be stepped down to 
find  the lowest effective dose. 
1. Based on severe asthma phenotyping in 
adults, novel molecular-targeted therapies may 
provide clinical benefits both through symptom 
control and abrogating the underlying pathogenesis of 
the disease. The clinical advantages of such evolving 
therapies should be weighed against possible safety 
concerns.
84   Approach to Patients with Severe Asthma 
Tanaffos 2015;14(2): 73-94 
 Table 2. Evidence on new treatments in severe asthma from randomized, double-blind, placebo-controlled, parallel- armed studies.  ACQ: asthma control questionnaire, 
AHR: airway hyper-responsiveness, AQLQ: asthma quality of life questionnaire, FeNO: level of nitric oxide in exhaled breath, FEV1: forced expiratory volume in 1 second,   
OCS: oral corticosteroids, PEFR: peak expiratory flow rate, SABA: short-acting beta-agonist, SEA: Severe Eosinophilic Asthma, TNFa: tumor necrosis factor-alfa, w: week. 
 
Reference Severity (n) Treatment Outcomes Summary results 
(183) Severe, OCS-dependent SEA patients, 
Omalizumab-treated (n=45) 
Mepolizumab in 
patients receiving 
maintenance OCS 
(5–35 mg/day) for ! 
6 months. 
Reductions in OCS use 
and exacerbation rate 
Patients previously treated with 
Omalizumab had similar OCS 
reduction (OR=2.15 vs. 2.53) and 
exacerbation rate reduction (33% 
vs. 29%) to those with no prior 
history. 
(175) Severe, with !2  
exacerbations in past year (n=621) 
Mepolizumab  
(75, 250 or 750 mg 
infusions at 4w), 
anti-IL-5, 52w 
Frequency of 
exacerbations 
Reduced exacerbations by 39 to 
52% in all doses. 
No effect on ACQ, AQLQ or FEV1. 
(174) Severe (n=34) SCH527123, 
CXCR2 receptor 
antagonist, 4w 
Altered sputum and 
neutrophil activation 
markers 
Reduced blood and sputum 
neutrophils. Reduced mild 
exacerbations. 
No reduction in ACQ score. 
(98) Moderate-to- 
severe 
(n=291) 
Lebrikizumab, anti-
IL13 antibody, 24w 
altered 
pre-bronchodilator 
FEV1 
Improved FEV1 compared to 
placebo, with greatest changes in 
high levels of periostin or FeNO 
group (post hoc analyses). 
No change in ACQ5. 
Exacerbations were 60% lower in 
the treated arm. 
(170) Poorly- controlled on high-dose inhaled 
CS (n=53) 
Reslimuzab,  
anti- IL-5, 12w 
ACQ 
FEV1 
Sputum eosinophils 
Improved ACQ score. 
Reduced sputum eosinophils. 
Improved FEV1. 
(171) Moderate-to- 
severe 
(n=294) 
AMG317,  
anti-IL- 4Ra 
antibody, blocks IL-
4 and IL-13, 12w  
ACQ scores, Frequency 
of exacerbations 
No  change in ACQ or 
exacerbations 
(104) Severe (n=61) Mepolizumab,  
anti-IL5, 50w 
Exacerbations 
Symptoms, FEV1, 
AQLQ, AHR, sputum and 
blood eosinophils 
Reduced exacerbations. Improved 
AQLQ. 
Reduced eosinophils. 
(97) Severe (n=20) Mepolizumab, 
anti-IL5, 50w 
Frequency of 
exacerbations, reduction 
in oral steroid  
Reduced exacerbations, 
eosinophils and OCS dose. 
(176) Severe (n=309) Golimumab,  
anti-TNFa, 24w 
FEV1, 
Exacerbations,  AQLQ, 
PEFR 
Unchanged FEV1. No reduction in 
exacerbations, AQLQ and PEFR. 
Notable adverse effects. 
(172) Severe, CS- dependent 
(n=44) 
Masitinib (3, 4.5 and 
6 mg/kg/day), c-kit 
and PDGFR 
tyrosine kinase 
inhibitor, 16w 
Oral CS dose, FEV1, 
ACQ 
No difference in OCS dose. 
ACQ improved, no difference in 
FEV1 
(184) Moderate-to- severe 
(n=115) 
Daclizumab, IL- 2R 
antibody, 20w 
Altered FEV1 (%) 
Frequency of 
exacerbations 
Improved FEV1. Reduction in 
daytime asthma scores and the 
use of SABA. 
Prolonged time to severe 
exacerbations. Reduced blood 
eosinophils. 
(173) Severe (n=26) SCH55700,  
anti- IL-5, 12w 
Sputum and blood 
eosinophils, symptoms, 
FEV1 
Reduced blood and sputum 
eosinophils. No other significant 
outcomes. 
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CONCLUDING REMARKS 
a. The RC-EIF comprising  experts in Iran held a problem-
oriented clinical forum in December 2014 to discuss the 
evidence and draw and agree  on a stance taken on 
severe asthma. The discussions and literature review 
revolved around: 1- The assessments needed to 
determine severe, difficult-to-control asthma, 2- 
Evaluating comorbidities and confounding factors, 3- 
Early phenotyping as an essential step in optimized 
therapy, and 4- Current treatment approaches. 
International guidelines were reviewed (based on the 
AGREE-II protocol appraising the international 
guidelines to define locally-adapted strategies) to reach 
a consensus. 
b. Severe asthma which remains difficult-to-control 
despite administration of combination of high dose ICS 
and long-acting bronchodilators poses a significant 
clinical challenge and an important health care 
problem. Education and awareness about asthma 
management as well as adherence to international 
(locally-adapted) guidelines and statements of experts   
are expected to improve health-care process and 
clinical outcomes in the management of severe asthma.  
c. Management of severe asthma needs a systematic 
approach to ensure a precise diagnosis, identify 
comorbidities and trigger factors and evaluate 
compliance. Severe asthma phenotyping is 
becoming an integral element of such a systematic 
approach as it would help optimizing   
treatments. The combination of ICS, LABA, 
LTRAs or oral theophylline is the current 
pharmacotherapy for severe, difficult-to-control 
asthma. Tiotropium bromide is a more recent 
effective add-on controller therapy to ICS. Severe 
refractory asthma often requires regular OCS use, 
thus the risk of steroid-related adverse events is 
almost always an issue.  The use of 
immunomodulatory and biologic therapies as an 
alternative approach has been considered with a 
wide variation in efficacy and safety profiles 
across trials.  
d. The expert panel of RC-EIF is determined to address 
other key issues with regard to the management of 
asthma in future discussion forums. The ultimate idea 
is to provide locally-adapted statements on various 
aspects of asthma care.  
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